Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 5,025 shares trading hands.
Mateon Therapeutics Trading Down 0.5 %
The company has a 50 day simple moving average of $0.03 and a 200-day simple moving average of $0.03.
About Mateon Therapeutics
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Read More
- Five stocks we like better than Mateon Therapeutics
- How to Start Investing in Real Estate
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- What Are Earnings Reports?
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- The 3 Best Fintech Stocks to Buy Now
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
